Browse by Phase
Phase 2 Clinical Trials
Phase 2 trials study whether a drug works in people with a specific disease or condition. These studies enroll 100–300 participants and also continue to evaluate safety.
Total Trials
1,083
Recruiting Now
1,083
Top Conditions in Phase 2
Frequently Asked Questions — Phase 2 Trials
What does a Phase 2 clinical trial evaluate?
Phase 2 trials assess whether a drug or treatment works in people with a specific disease or condition. Enrolling 100–300 participants, these studies collect preliminary efficacy data while continuing to monitor safety and identify the optimal dosing regimen. A successful Phase 2 outcome is required to advance to large-scale Phase 3 testing.
How long do Phase 2 trials typically take?
Phase 2 clinical trials typically run for 1–4 years, depending on the condition, endpoint complexity, and enrollment rate. Rare disease trials or those with long-term outcome measures may run longer. Many sponsors run Phase 2 studies at multiple sites simultaneously to accelerate recruitment.
Who can participate in a Phase 2 clinical trial?
Eligibility for Phase 2 trials is defined by specific inclusion and exclusion criteria. Participants are typically patients diagnosed with the condition under study and may or may not have received prior treatment. Age, disease stage, comorbidities, and laboratory values are common eligibility factors. Review each trial's criteria on ClinicalTrials.gov for specific requirements.
Active Phase 2 Studies
NCT06504147 Phase 2
Recruiting
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With...
Condition
Peritoneal Carcinomatosis
Enrollment
114 pts
Location
United States, Belgium, Italy
Sponsor
Oncoinvent Solutions AS
NCT06831149 Phase 2
Recruiting
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstructi...
Condition
Squamous Cell Carcinoma
Enrollment
225 pts
Location
United States
Sponsor
Matthew Spector
NCT06997900 Phase 2
Recruiting
Menopur And Rekovelle Combination Study Version 2.0
Condition
IVF
Enrollment
200 pts
Location
Canada
Sponsor
Clinique Ovo
NCT06430736 Phase 2
Recruiting
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
Condition
Myeloma
Enrollment
100 pts
Location
Switzerland
Sponsor
Insel Gruppe AG, University Ho
NCT06904911 Phase 2
Recruiting
Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mech...
Condition
Acute Ischemic Stroke From Large Vessel Occlusion
Enrollment
20 pts
Location
United States
Sponsor
University of Pennsylvania
NCT06816771 Phase 2
Recruiting
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV f...
Condition
Rhabdomyosarcoma, Recurrent, Refractory
Enrollment
38 pts
Location
China
Sponsor
Shandong Cancer Hospital and I
NCT04166006 Phase 2
Recruiting
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autolo...
Condition
Head Neck Tumors
Enrollment
51 pts
Location
Italy
Sponsor
Istituto Romagnolo per lo Stud
NCT07438106 Phase 2
Recruiting
A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) a...
Condition
Locally Advanced Pancreatic Cancer With KRAS G12D Mutation
Enrollment
30 pts
Location
China
Sponsor
The First Affiliated Hospital
NCT07726433 Phase 2
Recruiting
Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Relate...
Condition
Chemotherapy-Induced Nausea and Vomiting (CINV)
Enrollment
56 pts
Location
China
Sponsor
Tianjin Medical University Can
NCT05704621 Phase 2
Recruiting
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer W...
Condition
Ovarian Cancer
Enrollment
124 pts
Location
South Korea
Sponsor
Korea University Guro Hospital
NCT07104812 Phase 2
Recruiting
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Condition
Mild Autonomous Cortisol Secretion
Enrollment
15 pts
Location
United States
Sponsor
Mayo Clinic
NCT06152731 Phase 2
Recruiting
HRD Tests for Ovarian cancER
Condition
Ovarian Cancer
Enrollment
88 pts
Location
France
Sponsor
Centre Francois Baclesse
NCT05785039 Phase 2
Recruiting
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Ad...
Condition
Urinary System Tumor
Enrollment
76 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C
NCT06781567 Phase 2
Recruiting
Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcino...
Condition
Adenoid Cystic Carcinoma
Enrollment
140 pts
Location
China
Sponsor
HitGen Inc.
NCT07202611 Phase 2
Recruiting
DC/NK Cell Therapy
Condition
Lung Cancer (NSCLC)
Enrollment
10 pts
Location
Taiwan
Sponsor
National Taiwan University Cli
NCT07551583 Phase 2
Recruiting
Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult P...
Condition
Hodgkin Lymphoma
Enrollment
15 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT07204639 Phase 2
Recruiting
Safety and Efficacy of CBP-0276 to Improve Severity and Quality of Life on Moder...
Condition
Psoriasis
Enrollment
100 pts
Location
Mexico
Sponsor
Clarent Biopharma, Inc.
NCT05557877 Phase 2
Recruiting
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Condition
Breast Carcinoma
Enrollment
60 pts
Location
United States
Sponsor
Mayo Clinic
NCT07175428 Phase 2
Recruiting
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Antic...
Condition
Atrial Fibrillation (AF)
Enrollment
1,200 pts
Location
United States, Argentina, Brazil
Sponsor
Regeneron Pharmaceuticals
NCT06296745 Phase 2
Recruiting
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma Th...
Condition
Leptomeningeal Metastasis
Enrollment
36 pts
Location
China
Sponsor
Guangzhou Medical University
NCT07770100 Phase 2
Recruiting
Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation T...
Condition
Head and Neck Cancer
Enrollment
35 pts
Location
United States
Sponsor
Mark Bernard
NCT06969807 Phase 2
Recruiting
Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kid...
Condition
Diabetic Kidney Disease (DKD)
Enrollment
120 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT07259707 Phase 2
Recruiting
Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed F...
Condition
Acute Myeloid Leukemia
Enrollment
25 pts
Location
China
Sponsor
First Affiliated Hospital of Z
NCT07084012 Phase 2
Recruiting
A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous In...
Condition
Acute Ischemic Stroke AIS
Enrollment
60 pts
Location
China
Sponsor
Shenzhen Wingor Biotechnology
NCT07252739 Phase 2
Recruiting
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants...
Condition
Malignant Neoplasm
Enrollment
140 pts
Location
United States, Chile, China
Sponsor
Merck Sharp & Dohme LLC
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology